Patents by Inventor Andrew FLYAK

Andrew FLYAK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus
    Publication number: 20240123050
    Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.
    Type: Application
    Filed: May 1, 2023
    Publication date: April 18, 2024
    Inventors: Drew Weissman, George M. Shaw, Justin R. Bailey, Stuart C. Ray, James Crowe, Jr., Andrew Flyak
  • Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus
    Patent number: 11660332
    Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 30, 2023
    Assignees: The Trustees of the University of Pennsylvania, The Johns Hopkins University, Vanderbilt Univeisily
    Inventors: Drew Weissman, George M. Shaw, Justin R. Bailey, Stuart C. Ray, James Crowe, Jr., Andrew Flyak
  • Hepatitis C virus gene sequences and methods of use therefor
    Patent number: 11596679
    Abstract: The present disclosure relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present disclosure provides a composition comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 7, 2023
    Assignees: VANDERBILT UNIVERSITY, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE JOHNS HOPKINS UNIVERSITY
    Inventors: James E. Crowe, Jr., Andrew Flyak, Justin Bailey, Stuart Ray, George Shaw
  • Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus
    Publication number: 20200222528
    Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.
    Type: Application
    Filed: April 27, 2018
    Publication date: July 16, 2020
    Inventors: Drew Weissman, George M. Shaw, Justin R. Bailey, Stuart C. Ray, James Crowe, Jr., Andrew Flyak
  • HEPATITIS C VIRUS GENE SEQUENCES AND METHODS OF USE THEREFOR
    Publication number: 20200188504
    Abstract: The present disclosure relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present disclosure provides a composition comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 18, 2020
    Applicants: Vanderbilt University, The Trustees of the University of Pennsylvania, The John Hopkins University
    Inventors: James E. CROWE, JR., Andrew FLYAK, Justin BAILEY, Stuart RAY, George SHAW